Only about 60 percent of people with diffuse large B-cell lymphoma, a common cancer of white blood cells, respond well to therapy. This cancer, as currently defined, is in fact two distinct diseases, according to new tests that use so-called gene chips to look at the activity of thousands of genes simultaneously.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.